Oncology

Your Article Summary

See Latest Articles

Surgical outcomes and survival after multiorgan resection for locally advanced gastric cancer
The American Journal of Surgery, 06/26/09

Ozer M et al. - In a trial to evaluate the efficacy of multiple organ resection for locally advanced (assumed T4) gastric cancer with regard to surgical morbidity, mortality, and survival, it was concluded thatmultiple organ resection is worthwhile with careful pt selection.

• 56 pts underwent potentially radical gastrectomy combined with invaded organ resection.
• Early and late results of multiorgan resection and clinicopathologic factors influencing these results were evaluated.

• 40 pts (71.4%) received 1 additional organ resection and 16 pts (28.6%) received 2 or more additional organ resections.
• Postoperative morbidity and mortality was 37.5% and 12.5%, respectively.
• Resection of 2 or more additional organs increased postoperative morbidity and advanced age increased mortality.
• 1- and 3-yr survival rates were 53.3% and 28.1%, respectively.
• Advanced age, lymph node metastasis, and resection of >1 additional organ were significant prognostic factors for survival.

Today in GI Oncology...keeping you current

Receive free subspecialty "5-minute updates" via email

Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
New England Journal of Medicine, 10/22/09

Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer
Journal of Clinical Oncology, 11/02/09

Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer
Journal of Clinical Oncology, 10/29/09

See All of GI Oncology